Navigation Links
Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
Date:9/22/2011

SAN DIEGO, Sept. 22, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the JMP Securities Healthcare Conference in New York. The presentation is scheduled for Wednesday, September 28 at 8:30 a.m. EDT (5:30 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant un
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Two new educational webinars hosted by ... ALS research and how the pharmaceutical industry can make life ... Challenge: Where Does the ALS Money Go? , Featuring guest ... Time: 1:30pm ET, Register to attend , This ... Cudkowicz, Julianne Dorn Professor of Neurology at Massachusetts General Hospital ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed outperformed 137 ... Summit in San Francisco to take first place in ... Valley investors and technology elites as the premier showcase ... Briteseed to move on to the final phase ... with other elite innovation finalists for a $125,000 cash ...
(Date:11/21/2014)... , Todd Martensen ... Mariano Rodríguez es elegid vicepresidente senior de desarrollo empresarial ... en marcha para comenzar de forma rápida la comercialización de ... aprobación en Europa   , KLOX ... los siguientes nombramientos: Todd Martensen ha ...
(Date:11/21/2014)... November 20, 2014 The ... policy research organization representing leading California academic institutions, ... PwC US today released a report ... sciences industry growth. The trend shows a 4 ... 2015 California Biomedical Industry Report indicates that, ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4
... mortality faced by patients at ... national average, EL SEGUNDO, Calif., July 7 ... those diagnosed with chronic,kidney failure and disease (CKD), significantly ... by both the Clinical,Performance Measures Report published in 2006 ...
... Takes Over From Bernard Barataud, EVRY, France, July ... new president to head the laboratory created in 1990 ... succeeds Bernard,Barataud, who has decided to hand over the ... then between 1999 and 2008., Yves Champey is ...
... July 3 Bioheart, Inc.,(Nasdaq: BHRT ) ... development,of autologous (patient-derived) cell therapies and devices for ... announced that its Board,of Directors appointed Howard J. ... Technology Officer, to serve as Chief Executive,Officer effective ...
Cached Biology Technology:Superior Patient Clinical Outcomes Confirms DaVita's Leadership Position on Quality Dialysis Care 2Superior Patient Clinical Outcomes Confirms DaVita's Leadership Position on Quality Dialysis Care 3A New President at the Head of the Genethon Laboratory 2Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer 2Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer 3
(Date:11/11/2014)... -- Forensicon, Inc., a Chicago -based digital ... promotion of Yaniv Schiff from Senior Computer ... new role as Director, he will lead company efforts ... and provide leadership within the company,s digital forensics practice ... Schiff joined Forensicon in 2006 and ...
(Date:11/7/2014)... conjunction with the Glendale and ... the Verdugos has announced the " GLENDALE - ... to keep the Verdugo Regional Crime Lab operational after its ... existence, the Lab has processed more than 400 DNA samples, ... "Because our number one priority is the wellbeing of ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3
... To promote the health of at-risk teenagers in Newark and ... The Horizon Foundation for New Jersey. ... to teach middle and high school students about nutrition, physical ... carried out by the Consortium for Pre-College Education in Greater ...
... of Anatomists has chosen Springer to publish its official ... issue will be published at Springer in April 2009. ... Anatomical Science International focuses on the morphological ... cellular, histological and gross anatomical studies. In addition ...
... world, nitrogen compounds are released to the atmosphere ... These pollutants are deposited to ecosystems as precipitation, ... downwind of their release point. The Catskill Mountains ... pointthough they contain little in the way of ...
Cached Biology News:Anatomical Science International joins Springer's publishing program 2Tree species composition influences nitrogen loss from forests 2
Request Info...
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... is an essential component of the COP9 ... various cellular and developmental processes. The CSN ... ubiquitin (Ubl) conjugation pathway by mediating the ... E3 ligase complexes. The complex is also ...
Biology Products: